We have located links that may give you full text access.
Identification of quinolone and colistin resistance genes in Escherichia coli strains isolated from mucosal samples of patients with colorectal cancer and healthy subjects.
Recent Patents on Anti-infective Drug Discovery 2019 June 11
INTRODUCTION: Antibiotic resistance and extensive use of antibiotics is one of the major causes of failure in antibiotic treatment. The purpose of this study was to investigate antibiotic resistance patterns and to identify resistance genes of quinolones and colistin in Escherichia coli. There are very few patents on E. coli isolated from colorectal cancer. So, this study demonstrated that some bacteria resistant to ciprofloxacin are not present resistance genes. As well as, new patterns for E. coli are presented for samples of patients with colorectal cancer.
MATERIALS AND METHODS: Of the three healthy, inflammatory bowel diseases (IBD) and colorectal cancer groups, 40 E. coli strains isolated after confirmation by biochemical and molecular methods. The susceptibility of isolates to antibiotics was investigated using disk diffusion test. After deoxyribonucleic acid (DNA) extraction, polymerase chain reaction (PCR) was used to identify genes encoding resistance to ciprofloxacin (qnr A, qnr B) and colistin (mcr-1).
RESULTS: The results showed that E. coli isolates from colorectal cancer patients had the highest resistance to piperacillin (67.5%), ceftazidime (47.5%), and cefepime (42.5%). Also, E. coli strains isolated from IBD patients showed resistance to antibiotic ceftazidime 13%. More than 95% of E. coli strains isolated from healthy people were susceptible to antibiotics. Based on the results, 18 (15%) E. coli strains were showed resistance to ciprofloxacin. The qnr A gene was detected in 61.11% isolate; however qnr B was detected in 9 (50%). Isolates resistant to colistin were not observed.
CONCLUSION: These findings indicate increased resistance of E. coli to ciprofloxacin in comparison with prior studies. Further research in this field will increase our knowledge and more effective exposure to the antibiotic resistance of the pathogenic microorganisms.
MATERIALS AND METHODS: Of the three healthy, inflammatory bowel diseases (IBD) and colorectal cancer groups, 40 E. coli strains isolated after confirmation by biochemical and molecular methods. The susceptibility of isolates to antibiotics was investigated using disk diffusion test. After deoxyribonucleic acid (DNA) extraction, polymerase chain reaction (PCR) was used to identify genes encoding resistance to ciprofloxacin (qnr A, qnr B) and colistin (mcr-1).
RESULTS: The results showed that E. coli isolates from colorectal cancer patients had the highest resistance to piperacillin (67.5%), ceftazidime (47.5%), and cefepime (42.5%). Also, E. coli strains isolated from IBD patients showed resistance to antibiotic ceftazidime 13%. More than 95% of E. coli strains isolated from healthy people were susceptible to antibiotics. Based on the results, 18 (15%) E. coli strains were showed resistance to ciprofloxacin. The qnr A gene was detected in 61.11% isolate; however qnr B was detected in 9 (50%). Isolates resistant to colistin were not observed.
CONCLUSION: These findings indicate increased resistance of E. coli to ciprofloxacin in comparison with prior studies. Further research in this field will increase our knowledge and more effective exposure to the antibiotic resistance of the pathogenic microorganisms.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app